Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 27

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 27
---
 series of debt securities:

| · | the title; |

| · | the principal amount being offered, and if a                          
 series, the total amount authorized and the total amount outstanding; |

| · | any limit on the amount that may be issued; |

| · | whether or not we will issue the series of debt                                 
 securities in global form, and if so, the terms and who the depository will be; |

| · | the maturity date; |

| · | the principal amount due at maturity, and whether                   
 the debt securities will be issued with an original issue discount; |

| · | whether and under what circumstances, if any,                                                                                          
 we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether 
 we can redeem the debt securities if we have to pay such additional amounts;                                                           |

| · | the annual interest rate, which may be fixed                                                                                           
 or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and 
 the regular record dates for interest payment dates or the method for determining such dates;                                          |

| · | whether or not the debt securities will be secured 
 or unsecured, and the terms of any secured debt;   |

| · | the terms of the subordination of any series 
 of subordinated debt;                        |

| · | the place where payments will be payable; |

| · | restrictions on transfer, sale or other assignment, 
 if any;                                             |

| · | our right, if any, to defer payment of interest     
 and the maximum length of any such deferral period; |

| · | the date, if any, after which the conditions                                                                                            
 upon which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional 
 redemption provisions and the terms of those redemptions provisions;                                                                    |

| · | the date, if any, on which, and the price at                                                                                            
 which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder’s 
 option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;           |

| · | whether the indenture will restrict our ability                                
 to pay dividends, or will require us to maintain any asset ratios or reserves; |

| · | whether we will be restricted from incurring